GDC-2394

Overview

GDC-2394 is an orally active and selective NLRP3 inhibitor, and also inhibits IL-1β with IC 50 s of 0.4 μM (human IL-1β) and 0.1 μM (mouse IL-1β). GDC-2394 inhibits NLRP3-induced caspase-1 activity without inhibiting NLRC4-dependent inflammasome activation. GDC-2394 could be used to study gouty arthritis.

Application

Products | Products > Disease Areas > Depression | Products > Disease Areas > Pain | Products > Disease Areas > Autoimmune Disease | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Digestive System Disease | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Neurological Disease | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > NOD-like Receptor (NLR) | Products > Signaling Pathways > Interleukin Related | Products > Signaling Pathways > Caspase

Product Information

• Catalog No.: HY-148258
• CAS No.: 2238822-07-4
• Molecular Formula: C20H25N5O4S
• Molecular Weight: 431.51
• Purity: 99.87%
• Storage: Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.08 mg/mL (4.82 mM); Clear solution
• Availability: In-stock

Source

Original product source